Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome From Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf043 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Seiji Nishikage und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, C-Peptide, Insulin Resistance, Insulin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Ministry of Health, Labour, and Welfare.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Type A insulin resistance syndrome (IRS), characterized by impaired insulin receptor function due to variants of the insulin receptor gene, manifests as severe insulin-resistant diabetes. Differentiation of type A IRS from type 2 diabetes on the basis of hyperinsulinemia can be challenging. Given the association between insulin receptor dysfunction and reduced insulin clearance, we evaluated the potential of the circulating C-peptide reactivity (CPR)/immunoreactive insulin (IRI) molar ratio, a marker of insulin clearance, for distinguishing type A IRS from type 2 diabetes.
Methods
We retrospectively analyzed CPR and IRI levels measured during a 75-g oral glucose tolerance test (OGTT) in 18 individuals with type A IRS and 126 with type 2 diabetes. Receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic performance of the CPR/IRI molar ratio and IRI levels.
Results
IRI levels were significantly higher and the CPR/IRI molar ratio significantly lower in individuals with type A IRS compared with those with type 2 diabetes. The area under the ROC curve for the CPR/IRI molar ratio at baseline, 1 hour, and 2 hours after OGTT initiation was 0.997 (sensitivity 100%, specificity 99.2%), 0.999 (sensitivity 100%, specificity 97.6%), and 0.997 (sensitivity 100%, specificity 95.1%), respectively. The CPR/IRI molar ratio demonstrated robust diagnostic performance regardless of body mass index or hyperinsulinemia severity.
Conclusion
The CPR/IRI molar ratio, both at baseline and during OGTT, exhibited higher sensitivity and specificity than IRI levels alone for distinguishing type A IRS from type 2 diabetes. This ratio may serve as a reliable clinical marker for early and accurate diagnosis of type A IRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
- Division of General Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
ORCID-Profile: Seiji Nishikage, Yushi Hirota, Tomofumi Takayoshi, Kai Yoshimura, Akane Yamamoto, Kazuhiko Sakaguchi, Wataru Ogawa
Förderung
- Ministry of Health, Labour, and Welfare
Zitieren
APA
Nishikage, S., Hirota, Y., Takayoshi, T., Yoshimura, K., Takeuchi, T., Hamaguchi, T., Ueda, M., Yamamoto, A., Sakaguchi, K., & Ogawa, W. (2025). Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome From Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf043
Vancouver
Nishikage S, Hirota Y, Takayoshi T, Yoshimura K, Takeuchi T, Hamaguchi T, et al. Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome From Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf043
BibTeX
@article{Nishikage2025,
author = {Nishikage, Seiji and Hirota, Yushi and Takayoshi, Tomofumi and Yoshimura, Kai and Takeuchi, Takehito and Hamaguchi, Tetsushi and Ueda, Mariko and Yamamoto, Akane and Sakaguchi, Kazuhiko and Ogawa, Wataru},
title = {Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome From Type 2 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf043}
}
EUVIMED